Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

More documents

Recommendations

Info

38Figure 3.2 Outcomes and planning 2002–2008Figure 3.3 LF at-risk populationAnnual Report on Lymphatic Filariasis 2003No. of IUs1412108642No. IUs4.03.53.02.52.01.51.00.5million peoplePopulation in millions86420Total pop.6.27 MAt-risk pop.3.43 MChapter 3 Programme implementation0% of at-risk population covered200210020032004Planned pop. coverage75502506.4200220052006Figure 3.4 Geographical coverage200720080.0Pop. reported to haveingested drugs24.52003Figure 3.5 MDA reported coverage%100908077.880.97060502002 2003Figure 3.6 IUs with reported coverage >65%Figure 3.7 Updated mapping status10080100 100Total: 77 IUs— 29 IUs 48 IUsUncertain Non-endemic Endemic60%4020020022003
BURKINA FASO39Endemicity statusEndemicNon-endemicUncertainAnnual Report on Lymphatic Filariasis 2003LF is a major health problem for Burkina Faso’s populationof approximately 13 million, all of whom are consideredto be at risk. The LF clinical manifestationsevaluated in sentinel sites show hydrocele and lymphoedemaprevalence of 2% and 0.6%, respectively.The health district is designated as the IU. Mapping ofLF completed in 2000 showed that all 53 health districtsare considered LF-endemic. The first round of MDA usingalbendazole and ivermectin began in 2001 in four IUs inthe southern part of the country. In 2002, 14 IUs wereunder the co-administration of the two drugs and an at-riskpopulation of 2.6 million was covered. The third round ofMDA in 2003 covered 31 IUs and 7 074 048 people, with areported coverage of 77.8% (range: 54.9% to 82.6%).Mapping using ICT cards revealed LF prevalence of 5% to57% for new districts that started MDA in 2003, and themf prevalence found in seven new sentinel sites rangedfrom 0.1% to 23.8 %. Between 2001 and 2003, 20 993 drugdistributors were trained, and 2961 people were trainedin disability prevention and control.Chapter 3 Programme implementationTable 3.3 Goal: to eliminate LF from Burkina Faso by 2015Objectives• To interrupt transmission of LF• To prevent LF-associated disabilityStrategies• Social mobilization: to build awareness of the programme is plannedaccording to local characteristics by local experts and backed up, wherepossible, by local political, religious and community leaders• To interrupt transmission using MDA and vector control as a supplementarymeasure, wherever feasible• Disability control, including self-help care involving intensive local hygiene• Building and sustaining partnerships• Programme management by strengthening management and technicalcapacity• Door-to-door drug distribution strategy, with some booths
Page 1 and 2: For further information about lymph
Page 3: WHO/CDS/CPE/CEE/2005.52GlobalProgra
Page 7 and 8: 3Report of the Technical Advisory G
Page 9 and 10: P R O G R A M M E H I G H L I G H T
Page 11: I N T R O D U C T I O N7This Annual
Page 14 and 15: 10Annual Report on Lymphatic Filari
Page 46 and 47: 42Figure 3.14 Outcomes and planning
Page 59 and 60: UNITED REPUBLIC OF TANZANIA55Endemi
Page 61 and 62: ZANZIBAR, UNITED REPUBLIC OF TANZAN
Page 63: 59AMERICAN PROGRAMME REVIEWGROUPAt
Page 86 and 87: 82Figure 3.100 Outcomes and plannin
Page 92 and 93:
88Figure 3.118 Outcomes and plannin
Page 94 and 95:
90Figure 3.124 Outcomes and plannin
Page 96 and 97:
92Annual Report on Lymphatic Filari
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
100Annual Report on Lymphatic Filar
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
114Figure 3.196 Outcomes and planni
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 127:
C H A P T E R 6FURTHER DOCUMENTATIO
Page 130 and 131:
Page 132 and 133:
Page 135 and 136:
ANNUAL REPORT FOR THE NATIONAL PROG
Page 137 and 138:
1332. PROGRAMME RESOURCES2.1 Please
Page 139 and 140:
1353.3 Interruption of transmission
Page 141 and 142:
1373.3.6a Report of MDA coverage by
Page 143 and 144:
1393.3.7 Surveys in sentinel sites
Page 145 and 146:
1413.3.10 Please attach a map of th
Page 147 and 148:
1434. SERIOUS ADVERSE EXPERIENCES (
Page 149 and 150:
A N N E X E SANNEX 3: LIST OF LF-EN
Page 151 and 152:
147RAPLOARPRGSAESEAROTAG-LFTDRUNDPU
Page 153 and 154:
149Drug administration and monitori
show all

Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?